Deerfield Management Ups Stake in Aerie Pharmaceuticals Inc (AERI)

In a new filing with the Securities and Exchange Commission, James E. Flynn of Deerfield Management, has revealed a 6.05% stake in Aerie Pharmaceuticals Inc (NASDAQ:AERI). Deerfield’s passive position amasses 1.42 million shares of the company, up from some 565,200 shares held as of the end of the first quarter of the year.

Aerie Pharmaceuticals

Among other investors that own shares of Aerie Pharmaceuticals Inc (NASDAQ:AERI) as of the end of March is Baker Bros. Advisors, led by Julian Baker and Felix Baker, which held almost 299,400 shares, according to their latest 13F filing. Joseph Edelman‘s Perceptive Advisors has reduced its exposure to the company by 30% during the first three months of the year, to 211,500 shares. On the other hand, Stuart Weisbrod‘s Iguana Healthcare Management has upped its stake by 87% to 210,000 shares.

Aerie Pharmaceuticals Inc (NASDAQ:AERI) is a small cap clinical-stage pharmaceutical company, which is specialized on products for therapy for the treatment of glaucoma and other eye diseases.

Disclosure: none

Biotech Insider Alert - $5 Stock To Hit $40

$200 Million Dollar Healthcare Hedge Fund's #1 Best Idea Right Now

The best healthcare hedge fund out there right now is one of the largest shareholders in this biotech stock. The fund returned more than 20% in each of the last 2 years with a virtually fully hedged portfolio, and it's sending out a BUY signal on this biotech stock. Get your FREE REPORT today (retail value of $300)

This is a FREE report from Insider Monkey. Credit Card is NOT required.
X

Thanks! An email with instructions is sent to !

Your email already exists in our database. Click here to go to your subscriptions

Insider Monkey returned 129% in 2.5 years!! Wondering How?

Download a complete edition of our newsletter for free!